Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma

Deshan F. Sebaratnam, Linda K. Martin, Supriya S. Venugopal, George Mangos, John Freiman, Paul de Souza, Annabelle Farnsworth, Karen Cheung, Richard A. Scolyer, Dédée F. Murrell*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Case Report: A 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAFV600E mutation status, an unexpected finding given his age. He died two weeks after presentation. Discussion: As our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.

Original languageEnglish
Pages (from-to)1409-1411
Number of pages3
JournalInternational Journal of Dermatology
Issue number11
Publication statusPublished - 1 Nov 2014
Externally publishedYes


Dive into the research topics of 'Diffuse melanosis cutis in the setting of BRAF<sup>V</sup><sup>600</sup><sup>E</sup> metastatic melanoma'. Together they form a unique fingerprint.

Cite this